Disparities in Use of Immunotherapies Persist After FDA Approval
Some disparities that existed before FDA approval persisted after approval, and some new disparities emerged after FDA approval.
Some disparities that existed before FDA approval persisted after approval, and some new disparities emerged after FDA approval.
The efficacy of many combination therapies may be due to independent drug action, not synergistic or additive effects.
Cancer incidence is relatively high among kidney transplant recipients with allograft survival times longer than 20 years.
For 5 of 6 actinic damage and skin cancer index stages, consensus-based recommendations developed
Johnson & Johnson said it was still investigating how traces of benzene were discovered in the sunscreens
ASCO outlined advances in oncology that were the most clinically meaningful or had the biggest scientific impact from October 2018 through September 2019.
The use of steroids for the treatment of immune-related adverse events may have survival consequences.
Increased odds of using multiple sun protection measures among organ transplant recipients.
Standardized incidence ratio peaked in patients who underwent transplantation in 1983-1987 period.
Key changes include new N category descriptors, more stage III subgroups, new M1D designation.